A detailed history of Tower Research Capital LLC (Trc) transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 38,411 shares of GILD stock, worth $3.61 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
38,411
Previous 122,790 68.72%
Holding current value
$3.61 Million
Previous $8.42 Million 61.79%
% of portfolio
0.09%
Previous 0.15%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$66.59 - $83.99 $5.62 Million - $7.09 Million
-84,379 Reduced 68.72%
38,411 $3.22 Million
Q2 2024

Aug 13, 2024

SELL
$63.15 - $72.88 $4.02 Million - $4.64 Million
-63,710 Reduced 34.16%
122,790 $8.42 Million
Q1 2024

May 15, 2024

SELL
$71.58 - $87.29 $1.04 Million - $1.27 Million
-14,560 Reduced 7.24%
186,500 $13.7 Million
Q4 2023

Feb 13, 2024

BUY
$73.27 - $83.09 $9.95 Million - $11.3 Million
135,782 Added 208.01%
201,060 $16.3 Million
Q3 2023

Nov 14, 2023

BUY
$73.94 - $80.67 $3.08 Million - $3.36 Million
41,632 Added 176.06%
65,278 $4.89 Million
Q2 2023

Aug 14, 2023

BUY
$76.01 - $86.7 $230,690 - $263,134
3,035 Added 14.73%
23,646 $1.82 Million
Q1 2023

May 09, 2023

SELL
$77.31 - $88.08 $1.84 Million - $2.09 Million
-23,782 Reduced 53.57%
20,611 $1.71 Million
Q4 2022

Feb 10, 2023

SELL
$62.32 - $89.47 $14.6 Million - $20.9 Million
-233,549 Reduced 84.03%
44,393 $3.81 Million
Q3 2022

Nov 10, 2022

BUY
$59.54 - $68.01 $4.02 Million - $4.6 Million
67,593 Added 32.13%
277,942 $17.1 Million
Q2 2022

Aug 15, 2022

SELL
$57.72 - $65.01 $10 Million - $11.3 Million
-173,719 Reduced 45.23%
210,349 $13 Million
Q1 2022

May 12, 2022

BUY
$57.92 - $72.58 $14.2 Million - $17.8 Million
245,623 Added 177.42%
384,068 $22.8 Million
Q4 2021

Feb 14, 2022

BUY
$64.88 - $73.64 $27,184 - $30,855
419 Added 0.3%
138,445 $10.1 Million
Q3 2021

Nov 15, 2021

BUY
$67.69 - $73.03 $6.01 Million - $6.48 Million
88,752 Added 180.12%
138,026 $9.64 Million
Q2 2021

Aug 16, 2021

SELL
$63.47 - $69.35 $10.1 Million - $11 Million
-158,898 Reduced 76.33%
49,274 $3.39 Million
Q1 2021

May 17, 2021

BUY
$60.0 - $68.46 $8.17 Million - $9.32 Million
136,093 Added 188.81%
208,172 $13.5 Million
Q4 2020

Feb 16, 2021

BUY
$56.65 - $64.55 $885,269 - $1.01 Million
15,627 Added 27.68%
72,079 $4.2 Million
Q3 2020

Nov 16, 2020

BUY
$62.1 - $78.08 $1.61 Million - $2.03 Million
25,952 Added 85.09%
56,452 $3.57 Million
Q2 2020

Aug 13, 2020

BUY
$72.34 - $84.0 $2.21 Million - $2.56 Million
30,500 New
30,500 $2.35 Million
Q1 2020

May 15, 2020

SELL
$62.63 - $80.22 $154,069 - $197,341
-2,460 Closed
0 $0
Q4 2019

Feb 07, 2020

SELL
$61.62 - $67.78 $861,324 - $947,428
-13,978 Reduced 85.03%
2,460 $160,000
Q3 2019

Nov 05, 2019

SELL
$62.51 - $69.0 $1.78 Million - $1.96 Million
-28,472 Reduced 63.4%
16,438 $1.04 Million
Q2 2019

Aug 13, 2019

BUY
$61.87 - $69.38 $1.7 Million - $1.91 Million
27,477 Added 157.61%
44,910 $3.03 Million
Q1 2019

May 14, 2019

BUY
$62.53 - $70.05 $1.08 Million - $1.21 Million
17,311 Added 14189.34%
17,433 $1.13 Million
Q4 2018

Feb 14, 2019

SELL
$60.54 - $79.0 $153,105 - $199,791
-2,529 Reduced 95.4%
122 $8,000
Q3 2018

Nov 13, 2018

SELL
$71.28 - $78.92 $4.59 Million - $5.08 Million
-64,360 Reduced 96.04%
2,651 $205,000
Q2 2018

Aug 15, 2018

BUY
$64.88 - $75.68 $4.33 Million - $5.05 Million
66,747 Added 25282.95%
67,011 $4.75 Million
Q1 2018

May 15, 2018

SELL
$72.84 - $88.8 $615,133 - $749,916
-8,445 Reduced 96.97%
264 $20,000
Q4 2017

Feb 09, 2018

BUY
$71.15 - $83.52 $273,571 - $321,134
3,845 Added 79.05%
8,709 $624,000
Q3 2017

Nov 14, 2017

BUY
$72.11 - $85.47 $350,743 - $415,726
4,864
4,864 $394,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.